Shui On Leung
Chief Executive Officer chez SINOMAB BIOSCIENCE LIMITED
Fortune : 26 M $ au 31/03/2024
Profil
Shui On Leung is the founder of Sinomab Bioscience Ltd., which was founded in 2001.
He holds the title of Chairman & Chief Executive Officer at Sinomab Bioscience Ltd.
from 2003 to the present.
Dr. Leung is currently the Director at Hong Kong Genome Institute.
In the past, he worked as the Associate Director-Molecular Biology Department at Immunomedics, Inc. from 1991 to 2000.
From 2000 to 2003, he served as the Managing Director at The Hong Kong Institute of Biotechnology Ltd.
Dr. Leung was also the Director at Novelmab Ltd.
from 2011 to 2018.
Dr. Leung obtained a doctorate degree from the University of Oxford in 1990.
He also holds undergraduate and graduate degrees from The Chinese University of Hong Kong, which were conferred in 1986.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SINOMAB BIOSCIENCE LTD.
11,88% | 31/01/2024 | 129 729 200 ( 11,88% ) | 26 M $ | 31/03/2024 |
Postes actifs de Shui On Leung
| Sociétés | Poste | Début |
|---|---|---|
| SINOMAB BIOSCIENCE LIMITED | Chief Executive Officer | 01/01/2003 |
| Hong Kong Genome Institute | Director/Board Member | - |
Anciens postes connus de Shui On Leung
| Sociétés | Poste | Fin |
|---|---|---|
| Novelmab Ltd. | Director/Board Member | 01/07/2018 |
| The Hong Kong Institute of Biotechnology Ltd. | Chief Executive Officer | 01/08/2003 |
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 01/07/2000 |
Formation de Shui On Leung
| University of Oxford | Doctorate Degree |
| The Chinese University of Hong Kong | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SINOMAB BIOSCIENCE LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
| The Hong Kong Institute of Biotechnology Ltd. | |
| Novelmab Ltd. | |
| Hong Kong Genome Institute |
